Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Natco Pharma gets...

    Natco Pharma gets USFDA nod to market renal disease drug

    Written by Ruby Khatun Khatun Published On 2017-08-16T09:00:03+05:30  |  Updated On 16 Aug 2017 9:00 AM IST
    Natco Pharma gets USFDA nod to market renal disease drug
    New Delhi: Natco Pharma on Monday said it has received approval from the US health regulator to market Lanthanum Carbonate chewable tablets used in treatment of patients with end stage renal disease.

    The company has received final approval from the US Food and Drug Administration (USFDA) to market Lanthanum Carbonate chewable tablets in various strengths, Natco Pharma said in a regulatory filing.

    "The product, as the first generic, will be launched shortly in the USA market," it added.

    Natco's Lanthanum Carbonate strengths are generic equivalent of Shire Development LLC's Fosrenol chewable tablets and are indicated to reduce serum phosphate in patients with end stage renal disease (ESRD).

    As per IMS MAT sales data, Fosrenol tablets had sales of USD 122.4 million during June 2017 in the US market.

    Natco and Lupin had entered into an agreement on September 1, 2008 to jointly commercialise generic equivalents of Fosrenol chewable tablets.
    agreementapprovalchewable tabletsend stage renal diseaseFosrenolgenericLanthanum CarbonateLupinmarketNatco pharmarenal diseaserenal disease drugserum phosphateShireUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok